Related Experiment Video
Updated: Jan 4, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Microbiota transplant therapy and autism: lessons for the clinic
James B Adams1, Thomas J Borody2, Dae-Wook Kang3
1School for Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, Arizona, USA.
Abstract:
Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (MTT), a type of intensive intestinal microbiota transplantation (IMT), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews IMT, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive MTT for autism.Expert opinion: An open-label study and a two-year follow-up suggest that MTT is relatively safe and effective in significantly reducing gastrointestinal disorders and autism symptoms, changing the gut microbiome structure, and increasing gut microbial diversity. Further research with larger, randomized, double-blind, placebo-controlled studies is warranted.
Insights
Microbiota Transplant Therapy (MTT) shows promise for reducing gastrointestinal issues and autism symptoms in children. This intensive intestinal microbiota transplantation approach also positively impacts the gut microbiome, increasing its diversity.
Area of Science:
- Gastroenterology
- Neurodevelopmental Disorders
- Microbiome Research
Background:
- Autism spectrum disorder (ASD) is frequently associated with chronic gastrointestinal (GI) disorders.
- Gut microbiome alterations are observed in individuals with ASD and GI symptoms.
- Intensive intestinal microbiota transplantation (IMT) is an emerging therapeutic approach.
Purpose of the Study:
- To review Microbiota Transplant Therapy (MTT) as a form of IMT for ASD.
- To discuss GI symptoms and gut bacteria in children with ASD.
- To summarize findings from intensive MTT studies in autism.
Main Methods:
- Review of existing literature on IMT, ASD, and GI disorders.
- Analysis of results from an open-label study of MTT in children with ASD.
- Examination of a two-year follow-up data.
Main Results:
- MTT appears relatively safe and effective for reducing GI disorders in ASD.
- MTT significantly decreased autism symptoms in the studied population.
- The therapy altered gut microbiome structure and increased microbial diversity.
Conclusions:
- MTT demonstrates potential as a therapeutic option for ASD with co-occurring GI issues.
- Further investigation using rigorous study designs is recommended.
- Larger, randomized, double-blind, placebo-controlled trials are needed to confirm efficacy and safety.
Related Concept Videos
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Microorganisms in Medicine and Therapeutics
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.

